|
A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder
RECRUITINGPhase 3Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Actively Recruiting
PhasePhase 3
SponsorOtsuka Pharmaceutical Development & Commercialization, Inc.
Started2026-10-08
Est. completion2029-05-26
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →
NCT07786454
Summary
This is a global, Phase 3, multicenter, open-label extension trial designed to evaluate the long-term safety, tolerability and efficacy of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult participants with generalized anxiety disorder (GAD) over a treatment period of 26 weeks.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Key Inclusion Criteria 1. Male or female participants at least 18 years of age at the time of informed consent 2. Completed one of the prior GAD Phase 3 studies involving SEP-363856 through Week 8 without discontinuation of trial intervention 3. Able to continue treatment without interruption, and is considered by investigator to potentially benefit from SEP-363856 4. Participant is willing and able to comply with study procedures and visit schedule 5. i) Females of childbearing potential: negative pregnancy test and agreement to use acceptable contraception ii) Males: agreement to follow protocol-defined contraception and reproductive restrictions Key Exclusion Criteria 1. Diagnosis other than GAD that is the primary focus of treatment 2. Clinically significant psychiatric or medical condition that may interfere with study participation 3. Lifetime history of meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for, or was diagnosed during the prior study with, a psychiatric disorder that would compromise accurate assessment of safety and efficacy outcomes 4. Clinically significant abnormal laboratory values or ECG findings 5. Significant suicide risk 6. Substance use/positive drug screen 7. Use of prohibited medications/therapies 8. Known sensitivity to SEP-363856
Conditions2
AnxietyGeneralized Anxiety Disorder
Interventions1
Locations2 sites
Florida
1 siteClinical Neuroscience Solutions, LLC
New York
1 siteBasil Clinical
Find trials near these locations
Related trials
- A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder — Otsuka Pharmaceutical Development & Commercialization, Inc.
- A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder — Otsuka Pharmaceutical Development & Commercialization, Inc.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorOtsuka Pharmaceutical Development & Commercialization, Inc.
Started2026-10-08
Est. completion2029-05-26
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →
NCT07786454